Go Pro
NASDAQ:MPLT

Maplight Therapeutics Q3 2025 Earnings Report

Maplight Therapeutics logo
$10.92 -0.40 (-3.53%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$10.88 -0.04 (-0.37%)
As of 09/18/2026 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Maplight Therapeutics EPS Results

Actual EPS
-$37.18
Consensus EPS
-$1.86
Beat/Miss
Missed by -$35.32
One Year Ago EPS
N/A

Maplight Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Maplight Therapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, December 4, 2025
Conference Call Time
7:00AM ET

Earnings Documents

Maplight Therapeutics Earnings Headlines

Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
MapLight Therapeutics, Inc. (MPLT)
See More Maplight Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Maplight Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maplight Therapeutics and other key companies, straight to your email.

About Maplight Therapeutics

Maplight Therapeutics (NASDAQ:MPLT) is a clinical-stage biopharmaceutical company focused on developing treatments for disorders of the central nervous system. The company’s research programs are aimed at addressing significant unmet needs in psychiatric and neurological diseases.

MapLight’s pipeline consists of investigational therapies designed to target biological pathways associated with conditions such as schizophrenia and other brain disorders. Its activities include drug discovery, clinical development and the evaluation of potential treatments through clinical trials.

The company’s products remain investigational and require successful clinical testing and regulatory review before they can be marketed. Publicly available information about MapLight Therapeutics’ broader commercial operations, geographic reach and leadership is limited.

View Maplight Therapeutics Profile